Pentetreotide - Pharm-Sintez

Drug Profile

Pentetreotide - Pharm-Sintez

Alternative Names: Octreotide, 111In; Oktreotid, 111In

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Pharm-Sintez
  • Class Cyclic peptides; Radiopharmaceutical diagnostics; Somatostatins
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; CNS cancer; Neuroendocrine tumours; Small cell lung cancer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top